Eli Lilly gets a short cut at FDA for abemaciclib; Calyxt files for $100M IPO

⇨ Looking to play catch-up with the leaders in the CDK 4/6 cancer field, Eli Lilly scored the inside track at the FDA for abemaciclib, now under review for breast cancer. The agency is giving the drug a priority review, shaving four months off the agency’s review schedule. “We are pleased that the FDA has granted abemaciclib Priority Review, both as a potential monotherapy and combination therapy [with fulvestrant] for patients with advanced breast cancer,” said Levi Garraway, senior vice president, global development and medical affairs, Lilly Oncology.

Andre Choulika

Calyxt, the ag bio gene editing company set up by Cellectis CEO Andre Choulika, has filed for a $100 million IPO. Citigroup, Jefferies and Wells Fargo Securities are acting as joint book-running managers for the proposed offering. BMO Capital Markets and Ladenburg Thalmann are acting as co-managers.

Neon Therapeutics has enlisted the gene editing experts at CRISPR Therapeutics in its neoantigen approach to developing new cell therapies. The two companies announced a research collaboration Monday morning. There were no financial details in the release.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->